Additionally, pathogenic mutations were identified in several key genes, including ARID1A, CDKN2A, KMT2A, NF1, and TP53, but further research is required to evaluate the potential of specific mutations in personalizing treatment strategies for MPNST. This evidence concerns the gene KMT2A and malignant peripheral nerve sheath tumor.